CD4 memory T cells constituted 5%, 9%, and 17% of tumor-infiltrating T cells in PR, SD, and surgical patients, respectively, suggesting that neoadjuvant therapy might encourage naïve CD4 T cell differentiation (Fig. 2E). Here, CD4 is linked to neoplasm.